Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7462.085 | 0.9495 | 0.7507 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7462.085 | 0.9913 | 0.9556 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7462.085 | 0.9975 | 0.9872 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7462.085 | 1.0232 | 1.1210 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7462.085 | 0.9531 | 0.7678 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7462.085 | 0.8714 | 0.4045 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7462.085 | 0.5701 | -0.5274 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7462.085 | 0.9081 | 0.5618 | 0.3896 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7463.084 | 0.9345 | 0.8285 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7463.084 | 0.9672 | 0.9137 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7463.084 | 0.9269 | 0.8089 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7463.084 | 0.9357 | 0.8316 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7463.084 | 0.9530 | 0.8765 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7463.084 | 0.9948 | 0.9862 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7463.084 | 0.7577 | 0.3856 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7463.084 | 0.8437 | 0.5974 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7463.084 | 0.1927 | -0.7734 | 0.7560 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7464.084 | 0.9616 | 0.9063 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7464.084 | 0.9842 | 0.9613 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7464.084 | 0.9522 | 0.8833 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7464.084 | 0.9376 | 0.8480 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7464.084 | 0.9484 | 0.8742 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7464.084 | 0.7894 | 0.4964 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7464.084 | 0.6718 | 0.2276 | 0.8152 | |
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7464.084 | 0.3552 | -0.4381 | 0.8152 |